Large scale, postlicensure, selective vaccination of Chilean infants with PRP-T conjugate vaccine: Practicality and effectiveness in preventing invasive Haemophilus influenzae type b infections

Pediatric Infectious Disease Journal

Volumn 15, Issue 3, 1996, Pages 216-222

  Lagos, Rosanna ^a,b   Horwitz, Isidoro ^b   Toro, Jorge ^c   Martin, Oriana San ^a   Abrego, Paulina ^a   Bustamante, Cecilia ^a   Wasserman, Steven S ^d   Levine, Orin S ^d   Levine, Myron M ^d  

^a Centro para Vacunas en Desarrollo Chile   (Chile)

^b Servicio de Salud Metropolitano Norte   (Chile)

^c Ministerio de Salud de Chile   (Chile)

^d UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

Haemophilus influenzae; Immunization; vaccines

Indexed keywords

DIPHTHERIA PERTUSSIS TETANUS HAEMOPHILUS INFLUENZAE TYPE B VACCINE; DIPHTHERIA PERTUSSIS TETANUS VACCINE; HAEMOPHILUS INFLUENZAE TYPE B VACCINE;

ARTICLE; CHILE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; HAEMOPHILUS INFLUENZAE TYPE B; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOSURVEILLANCE; INFANT; INFECTION PREVENTION; INFLUENZA; INFLUENZA VACCINATION; MULTICENTER STUDY; PATIENT COMPLIANCE; PREGNANCY COMPLICATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEROCONVERSION;

CHILE; DIPHTHERIA-TETANUS-PERTUSSIS VACCINE; HAEMOPHILUS INFECTIONS; HAEMOPHILUS INFLUENZAE; HAEMOPHILUS VACCINES; HUMANS; INCIDENCE; INFANT; POLYSACCHARIDES, BACTERIAL; VACCINATION; VACCINES, COMBINED; VACCINES, CONJUGATE;

EID: 0029988370     PISSN: 08913668     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006454-199603000-00008     Document Type: Article

References (33)

1. Clemens JD, Stanton BF. Longer term evaluation of vaccine efficacy: methodological issues for Phase III and Phase IV trials. In: Woodrow G, Levine MM, eds. New generation vaccines? New York: Marcel Dekker, 1990:51-68.
2. 1a.Clemens JD, Brenner R, Rao M, Tafari N, Lowe C. Evaluating new vaccines for developing countries: efficacy or effectiveness? JAMA 1996;275:390-7.
3. Orenstein WA, Bernier RH, Hinman AR. Assessing vaccine efficacy in the field: further observations. Epidemiol Rev 1988;10:212-41.
4. Comstock GW. Evaluating vaccination effectiveness and vaccine efficacy by means of case-control studies. Epidemiol Rev 1994;16:77-89.
5. Comstock GW. Vaccine evaluation by case-control or prospective studies. Am J Epidemiol 1990;131:1205-7.
6. Smith PG, Rodrigues LC, Fine PEM. Assessment of the protective efficacy of vaccines against common diseases using case-control and cohort studies. Int J Epidemiol 1984;13:87-93.
7. Shapiro ED, Ward J. The epidemiology and prevention of disease caused by Haemophilus influenzas type b. Epidemiol Rev 1991;13:113-42.
8. Schneerson R, Barrera O, Sutton A, Robbins JB. Preparation, characterization and immunogenicity of Haemophilus influenzas type b polysaccharide-protein conjugates. J Exp Med 1980;152:361-76.
9. Anderson P, Pichichero ME, Insel RA. Immunogens consisting of oligosaccharides from the capsule of Haemophilus influenzae type b coupled to diphtheria toxoid or CRM197. J Clin Invest 1985;76:52-59.
10. Marburg S, Jorn D, Tolman RL, et al. Bimolecular chemistry of macromolecules: synthesis of bacterial polysaccharide conjugates with Neisseria meningitidis membrane protein. J Am Chem Soc 1986;108:5282-7.
11. Decker MD, Edwards KM, Bradely R, Palmer P. Comparative trial in infants of four conjugate Haemophilus influenzae type b vaccines. J Pediatr 1990;120:184-9.
12. Peltola H, Kilpi T, Antila M. Rapid disappearance of Haemophilus influenzae type b meningitis after routine childhood immunisation with conjugate vaccines. Lancet 1992; 340:592-4.
13. Jonsdottir KE, Steingrimsson O, Olafsson O. Immunisation of infants in Iceland against Haemophilus influenzae type b. Lancet 1992;340:252-3.
14. Booy R, Hodgson S, Carpenter L, et al. Efficacy of Haemophilus influenzae type b conjugate vaccine PRP-T. Lancet 1994; 344:362-6.
15. Adams WG, Deaver KA, Cochi SL, et al. Decline of childhood Haemophilus influenzae type b (Hib) disease in the Hib vaccine era. JAMA 1993;269:221-6.
16. Takala AK, Eskola J, Leinonen M, et al. Reduction of oropharyngeal carriage of Haemophilus influenzae type b (Hib) in children immunized with an Hib conjugate vaccine. J Infect Dis 1991;164:982-6.
17. Ferreccio C, Ortiz E, Astroza L, Rivera C, Clemens J, Levine MM. A population-based retrospective assessment of the disease burden resulting from invasive Haemophilus influenzae in infants and young children in Santiago, Chile. Pediatr Infect Dis J 1990;9:488-94.
18. Ferreccio C, Clemens JD, Avendaño A, et al. The clinical and immunologic response of Chilean infants to Haemophilus influenzae type b polysaccharide-tetanus protein conjugate vaccine coadministered in the same syringe with diphtheriatetanus toxoids-pertussis vaccine at two, four and six months of age. Pediatr Infect Dis J 1991;10:764-71.
19. Avendaño A, Ferreccio C, Lagos R, et al. Haemophilus influenzae type b polysaccharide-tetanus protein conjugate vaccine does not depress serologic responses to diphtheria, tetanus or pertussis antigens when coadministered in the same syringe with diphtheria-tetanus-pertussis vaccine at two, four and six months of age. Pediatr Infect Dis J 1993; 12:638-43.
20. Bijlmer HA. World-wide epidemiology of Haemophilus influenzae meningitis: industrialized versus nonindustrialized countries. Vaccine 1991;9 (Suppl):S5-9.
21. Ward J. Prevention of invasive Haemophilus influenzae type b disease: lessons from vaccine efficacy trials. Vaccine 1991;9 (Suppl):S17-24.
22. Moxon ER. Conclusion. Vaccine 1991;9 (Suppl):S44.
23. Black SB, Shinefield HR, Fireman B, Hiatt R, Polen M, Vittinghoff E. Efficacy in infancy of oligosaccharide conjugate Haemophilus influenzae type b (HbOC) vaccine in a United States population of 61 080 children. Pediatric Infect Dis J 1991;10:97-104.
24. Fritzell B, Plotkin S. Efficacy and safety of a Haemophilus influenzae type b capsular polysaccharide-tetanus protein conjugate vaccine. J Pediatr 1992;121:717-22.
25. Aylward B, Kane M, Batson A, Scott RM. A framework for the evaluation of vaccines for use in the expanded programme on immunization. Vaccine 1994;12:1155-9.
26. Kilian M. Haemophilus. In: Lennette EH, Balows A, Hausler WJ Jr, Shadomy HJ, eds. Manual of clinical microbiology. 4th ed. Washington, DC: American Society for Microbiology, 1985:387-93.
27. Donner A, Klar N. Methods for comparing event rates in intervention studies when the unit of allocation is a cluster. Am J Epidemiol 1994;140:279-89.
28. Henderson RH, Keja K, Galazka AM, Chan CA. Reaping the benefits: getting vaccines to those who need them. In: Woodrow G, Levine MM, eds. New generation vaccines. New York: Marcel Dekker, 1990:69-82.
29. State of the World's Children, 1993. Cambridge, UK: Oxford University Press, 1994.
30. Levine OS, Ortiz E, Contreras R, et al. Cost-benefit analysis for the use of Haemophilus influenzae type b conjugate vaccine in Santiago, Chile. Am J Epidemiol 1993;137:1221-8.
31. Lagos R, Levine O, Losonsky G, Bustamante C, Levine MM. A field evaluation of the impact of single syringe co-administration of Haemophilus influenzae type b and diphtheria-tetanus-pertussis vaccines on the serologic response to pertussis antigens and clinical protection against pertussis [Abstract]. Presented at the Twenty-first International Congress of Pediatrics, Cairo, Egypt, September, 1995.
32. Clemens JD, Ferreccio C, Levine MM, Horwitz I, Rao MR, Edwards KM. Impact of Haemophilus influenzae type b polysaccharide-tetanus protein conjugate vaccine on responses to concurrently administered diphtheria-tetanuspertussis vaccine. JAMA 1992;267:673-8.
33. The Gambia Hepatitis Study Group. The Gambia hepatitis intervention study. Cancer Res 1987;47:5782-7.